Prostrakan Share Discussion Threads

[ricartonl] 07/12/2007 14:30

Prostrakan Board Change

RNS Number:4687J
ProStrakan Group plc
07 December 2007


ProStrakan Group plc


Peter Allen takes up position as Chairman of ProStrakan.


Galashiels, Scotland, 7th December, 2007 - ProStrakan Group plc (LSE: PSK), the
international specialty pharmaceutical company, announced on 30th October, 2007
that its co-founder and Chairman, Harry Stratford OBE, had informed the Board of
his intention to retire as Chairman at the end of 2007. The Company also
announced that Peter Allen, a Non-Executive Director since 2005, had accepted
the Board's invitation to replace him.

ProStrakan announces that the formal handover took place at the Company's Board
meeting which was held yesterday (6th December, 2007).

[ricartonl] 05/12/2007 15:27

20% rise from the bottom

[waldron] 03/12/2007 08:46

Prostrakan gets approval for UK launch of Adcal-D3 soluble vitamin tablets




LONDON (Thomson Financial) - Specialty pharma company ProStrakan Group PLC
said it has received Medicines and Healthcare products Regulatory Agency's
(MHRA) approval for the launch of Adcal-D3 Dissolve 1500mg/400IU effervescent
tablets in the UK.
The tablets are a new, lemon flavoured, soluble formulation of the company's
market-leading calcium vitamin D supplement, Adcal-D3 -- used as an adjunct to
specific therapy for the treatment of osteoporosis.
ProStrakan said Adcal-D3 Dissolve will be launched in the UK in January 2008
in packs of 56 tablets at an NHS price of 4.99 stg. ProStrakan derived revenues
of 6.6 mln stg from product sales of Adcal-D3 in the first quarter this year.

[e-mail]
ypv/slm

[grimraider] 29/11/2007 20:00

Recovery? or another false dawn? any views out there

[grimraider] 28/11/2007 20:48

Yep - the good doctor had "positive press" in the Scotsman!

[password] 28/11/2007 18:13

Did I miss somthing??

[grimraider] 21/11/2007 18:16

Interesting, but the fact that only Tostran of their 2 new drugs has been approved for use by NHS Scotland, and that in a restricted way - in patients who cant take oral medication and that based on the fact that it is less expensive than the patch - Retrogesic appears to have been refused 3 times!! only 50% success in its home market, and even then with restrictions!!





Launching without good Healtheconomic data appears to be increasingly fatal, question is does Prostrakan have the skill base to provide the type of healtheconomic support for high priced branded generics

[trannie] 21/11/2007 14:05

Perhaps this explains the sudden further drop.


If we cant believe what they are saying about this drug, what can we believe ?

[grimraider] 20/11/2007 12:16

Hi Trannie

Looks rather grim, question is how much further can it fall, trends across Pharma dont look good, but this one looks even worse, yet nothing being done/communicated by company to bolster share price

[trannie] 20/11/2007 10:46

Grimraider - 21 Sep'07 - 18:30 - 115 of 127
Hey Trannie, looks like a "bounce"

Hi Grimraider - Looks like the trampoline of spin and hype has developed a hole ?

[ricartonl] 19/11/2007 14:25

quiet here, gravity has hold of the SP

[grimraider] 30/10/2007 14:03

Interesting news today

[grimraider] 26/10/2007 17:45

Oh yes - who is doing the selling?

[ricartonl] 26/10/2007 12:14

solid buying today

[grimraider] 22/10/2007 13:57

hmm, saw a flight of pigs the other evening

[philipsaxon] 22/10/2007 08:45

anyone get the feeling we're going to see this one make a strong comeback sometime soon?

[ariane] 28/9/2007 07:41

Prostrakan Regulatory Update


RNS Number:7016E
ProStrakan Group plc
28 September 2007

Regulatory Update


Galashiels, Scotland, 28 September, 2007 - ProStrakan Group plc (LSE: PSK), the
international specialty pharmaceutical company, today provides the market with
an update on the progress of a number of products undergoing EU approvals
processes following yesterday's EMEA meetings:


* Rapinyl EU approval process enters extended phase
* Droperidol receives EU approval



Rapinyl - breakthrough cancer pain. This patient-friendly formulation of
fentanyl, a long-established opioid used for the management of episodes of
severe breakthrough pain experienced by cancer patients who are already
receiving opioid analgesics, entered the EU Decentralised Procedure (DCP) last
year. Of the 25 member states involved in the DCP for Rapinyl, 21 consider this
product to be approvable. Because consensus among all 25 member states has been
required in the process so far, the product will now be referred for review by
the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMEA), where a majority decision is sufficient to gain
approval. The exact timings of the CHMP process are not yet clear, but the
Company believes that the approval process will extend into 2008. First
launches are now likely to commence from the end of 2008.



Droperidol (Xomolix) - post-operative nausea and vomiting. This branded,
injectable drug, used primarily in hospitals for the prevention and treatment of
post-operative nausea and vomiting, has now successfully completed the European
Decentralised Procedure (DCP). Droperidol is already marketed in eight European
countries, including France, The Netherlands and Portugal. Today's news means
ProStrakan can market Droperidol (branded as Xomolix) across other EU markets,
including Germany, Italy and Spain, once national licences have been issued. We
intend to commence EU launches in 2008.





Further enquiries:

ProStrakan
Dr Wilson Totten, Chief Executive Tel: [phone]
Callum Spreng, Corporate Comms Director


Financial Dynamics Tel: [phone]
David Yates/Ben Brewerton





Notes to Editors:


ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical
company engaged in the development and commercialisation of prescription
medicines for the treatment of unmet therapeutic needs in major markets.



ProStrakan's head office and development facilities are situated in Galashiels
in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products
are handled by commercial subsidiaries in the UK, France, Germany, Spain and
other EU countries. www.prostrakan.com




This information is provided by RNS
The company news service from the London Stock Exchange
END

MSCDGGZLKRVGNZG

[ariane] 27/9/2007 08:16

Novartis Ag Prostrakan, Galapagos get 3rd antibody milestone payment from Novartis


LONDON (Thomson Financial) - ProStrakan Group PLC said it and Galapagos NV
have received third antibody milestone payments from Novartis worth 1.5 mln usd.
Of the total amount, 1.125 mln usd goes to Prostrakan as per the terms of
its 2006 agreement with Galapagos.
Prostrakan and its former unit ProSkelia SASU had entered into an agreement
with Novartis in Sept 2006 under which total milestones could eventually exceed
100 mln usd.
ProSkelia was later acquired by Galapagos in Dec 2006 resulting in the
collaboration being transferred to Galapagos.
Under the terms of the acquisition of ProSkelia, Galapagos and ProStrakan
split milestone and royalty income from existing agreements in the ratio of 25
pct for Galapagos and 75 pct for ProStrakan.

[e-mail]
ukn/jfr

[grimraider] 21/9/2007 19:30

Hey Trannie, looks like a "bounce"

[password] 17/9/2007 17:04

Anyone like to comment as to what is going on, relatively high volume of transactions and downwards price despite apparently good interim results

[password] 13/9/2007 16:13

Might do, but looks almost like someone(s) are dumping a lot of shares - vol is high for this one